These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38323727)

  • 1. Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip.
    Lin KJ; Turner KC; Hassan HE; Harnisch LO; Davis JD; DiCioccio AT
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):621-630. PubMed ID: 38323727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
    Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
    Tiseo PJ; Kivitz AJ; Ervin JE; Ren H; Mellis SJ
    Pain; 2014 Jul; 155(7):1245-1252. PubMed ID: 24686255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
    Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
    Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
    Schnitzer TJ; Marks JA
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
    Dakin P; Kivitz AJ; Gimbel JS; Skrepnik N; DiMartino SJ; Emeremni CA; Gao H; Stahl N; Weinreich DM; Yancopoulos GD; Geba GP
    Ann Rheum Dis; 2021 Apr; 80(4):509-517. PubMed ID: 33199274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
    Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
    Othman AA; Tran JQ; Tang MT; Dutta S
    Clin Pharmacokinet; 2014 Oct; 53(10):907-18. PubMed ID: 25212703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.
    Cohen SB; Proudman S; Kivitz AJ; Burch FX; Donohue JP; Burstein D; Sun YN; Banfield C; Vincent MS; Ni L; Zack DJ
    Arthritis Res Ther; 2011 Jul; 13(4):R125. PubMed ID: 21801403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.